Insurance companies have specific rules about which medications theyll cover
Ozempic Lawsuit Timeline & News July 2026 July 1, 2026: MDL Over Alleged Ozempic, GLP-1 Side Effects Continues To Grow The federal GLP-1 MDL, which accuses the manufacturers of drugs like Ozempic of failing to warn patients of potential side effects, continues to add cases
Aim to: Take small bites and chew thoroughly Put utensils down between mouthfuls Allow at least 2030 minutes per meal Stop eating at the first sign of fullness, even if the plate is not empty Meal timing also matters

In a 30-week clinical trial of patients with uncontrolled T2D, 70% achieved a hemoglobin A1c (HbA1c or A1c) below 7% while taking 1 mg weekly injections of Ozempic.[2] Rybelsus is a once-daily pill and the first oral GLP-1 semaglutide medication.[3] It is used to lower blood sugar in adults with T2D.[3] In a 26-week clinical trial of adults with uncontrolled T2D, 77% achieved an A1c below 7% while taking 14 mg of Rybelsus.[3] Rybelsus is used with diet and exercise and may be prescribed as a monotherapy or alongside other T2D medications.[3] It may also be prescribed off-label for weight management in some patients without diabetes.[9] Semaglutide side effects Regardless of brand name, semaglutide may cause several side effects.[1-3] Common side effects include: Nausea Vomiting Diarrhea Abdominal pain Constipation More serious risks may include: Pancreatitis Acute gallbladder disease Hypersensitivity reactions Diabetic retinopathy Hypoglycemia (low blood sugar) Acute kidney injury Thyroid C-cell tumors The safety of semaglutide in individuals with a history of pancreatitis or during pregnancy remains unclear.[1-3] Semaglutide should not be used in: Patients with a personal or family history of medullary thyroid carcinoma (MTC) Patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) If you are planning to become pregnant, semaglutide should be discontinued at least two months before conception.[1-3] How to get a semaglutide prescription online Getting a semaglutide prescription requires an evaluation by a healthcare professional

CrossRef MASLD as a systemic metabolic disease: expanding the scope of cardiovascular-kidney-metabolic (CKM) syndrome Xiao-Dong Zhou, Qiong-Yue Fan, Giovanni Targher, Christopher D